What’s new?

The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 and
tyrosine kinase-2 (TYK2).
Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with moderate to severe plaque psoriasis in the POETYK study program. The orally administered active ingredient has now been approved in the USA, the EU and several other countries. Current analyses report on the efficacy and safety of deucravacitinib over a period of up to three years.